ArticleBMJ health & care informatics2025
Mitigated deployment strategy for ethical AI in clinical settings.
Article in BMJ health & care informatics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Clinical diagnostic tools can disadvantage subgroups due to poor model generalisability, which can be caused by unrepresentative training data. Practical deployment solutions to mitigate harm for subgroups from models with differential performance have yet to be established. This paper will build on existing work that considers a selective deployment approach where poorly performing subgroups are excluded from deployments. Alternatively, the proposed 'mitigated deployment' strategy requires safety nets to be built into clinical workflows to safeguard under-represented groups in a universal deployment. This approach relies on human-artificial intelligence collaboration and postmarket evaluation to continually improve model performance across subgroups with real-world data. Using a real-world case study, the benefits and limitations of mitigated deployment are explored. This will add to the tools available to healthcare organisations when considering how to safely deploy models with differential performance across subgroups.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.